Condition: Spinal Cord Injury · Safety · Clinical Trials · Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury
This description comes directly from the study's public registry record.
Michael LEE · +86 21 64027719 · CEO@xellsmart.com
Mao Pang, prof and M.D · +86-020-85252015 · pangmao6@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06976229